Navigation Links
Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome
Date:4/4/2008

Japanese and Other Ethnic Minorities at Increased Risk

BALTIMORE, April 4, 2008 /PRNewswire/ -- Newly published data by Dr. J. Barthelow Classen in The Open Endocrinology Journal shows a 50% reduction of type 2 diabetes occurred in Japanese children following the discontinuation of a single vaccine, a vaccine to prevent tuberculosis. This decline occurred at a time when there is a global epidemic of type 2 diabetes and metabolic syndrome, which includes obesity, altered blood cholesterol levels, high blood pressure, and increased blood glucose resulting from insulin resistance.

Classen proposes a new explanation for the epidemic of both insulin dependent diabetes (type 1 diabetes), which has previously been shown to be caused by vaccines and non insulin dependent diabetes (type 2 diabetes). Upon receipt of vaccines or other strong immune stimulants some individuals develop a hyperactive immune system leading to autoimmune destruction of insulin secreting cells. Other individuals produce increased cortisol, an immune suppressing hormone, to suppress the vaccine induced inflammation. The increased cortisol leads to type 2 diabetes and metabolic syndrome. Japanese children have increased cortisol secretion following immunization compared to White children and this explains why Japanese have a relative high rate of type 2 diabetes but low rate of insulin dependent diabetes compared to Whites. The lower cortisol response attributed to type 1 diabetes and the higher cortisol response attributed to type 2 diabetes explains why type 1 diabetics are generally leaner than type 2 diabetics since elevated cortisol causes weight gain.

"The current data shows that vaccines are much more dangerous than the public is lead to believe and adequate testing has never been performed even in healthy subjects to indicate that there is an overall improvement in health from immunization. The current practice of vaccinating diabetics as well as their close
'/>"/>

SOURCE Classen Immunotherapies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
2. Clinical trial will test new HIV/AIDS vaccine
3. Researchers Successfully Test Ebola Vaccines
4. MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk
5. HIV Vaccine Funding: Enough is Enough, Says AHF in Baltimore Sun
6. NIAID to convene HIV Vaccine Summit
7. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
8. UNC, Harvard develop inhaled TB vaccine
9. U.S. Health Officials Back Off Preference for New MMRV Vaccine
10. Inhaled tuberculosis vaccine more effective than traditional shot
11. HPV vaccine reduces abnormal pap test results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...he University of Texas Health Science Center at Ho...ce in Aging Studies (TEXAS), to promote geriatrics...million award from the Donald W. Reynolds Foundati...ll allow us to teach geriatric medicine principles...to practicing physicians. With the reach of Lyndon...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- The Providence Service,C...Craig A. Norris, the Company,s,Chief Operating Of...f,Directors. Mr. Norris, appointment fills the v...en I. Geringer and returns the board to six member... the Board. , Mr. Norris, age 41, has been ...
(Date:11/21/2008)...ved effective against Lennox-Gastaut syndrome , ...w drug called Banzel (rufinamide) has been approve...f epilepsy called Lennox-Gastaut syndrome, the U.S..., The approval was based on results of a four-mo...o 30. Compared to patients who took a placebo, tho...
(Date:11/21/2008)...21 New research at Wes...eless, spitless tobacco product aimed at young adu... that RJ Reynolds, Camel Snus - touted as a social...surprisingly high levels of nicotine. , , "...snuff products," said Bruce Adkins of the state Di...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3
...ty for superstition and marketing to come together... are over-booked and Live Earth concerts as well a...s take place that day. "Number 7 has a magic sacr...ng luck," said numerologist Jean-Daniel Fermier. S...
...ina is expected to replace France as the world's t...ewed by a foreign news agency said China received ...ivals from Hong Kong, Macau, and Taiwan, compared ...978. They said that while tourism growth in Franc...
... moving out from her Sierra Towers apartment to le...apartment is at a very happening place, so the 'pa...ken car crash has decided not to go back there onc...rapy. "The Sierra Towers is party central," New Y...
...aginal lubricants control the growth of infection ... cervical cancer. The study was conducted by a t...ional Cancer Institute, Bethesda, Maryland. The p...experiments was that HPV survive only in humans, m...
Other Medicine News:Health News:A Lucky Number? 7/7/07 2Health News:A Lucky Number? 7/7/07 3Health News:China to Replace France as World's Top Tourism Destination by 2014 2Health News:Vaginal Lubricants can Reduce Cervical Cancer Risk 2
(Date:11/20/2008)...LE, Calif., Nov. 20 Bion... will present results from the Phase 1B,clinical ...tastatic breast,cancer, BZL101, at the Society fo...erence in Atlanta, Georgia. The Company,s oral pr... and will be presented as a part of the Best of th...
(Date:11/20/2008)...SO, Norway, November 20 The Scandi...arma has announced results of studies on its,lead...AC in Washington, DC,the studies showed that the...cteriocidal effect, significantly better towards k...ogenes than marketed gold standard drugs. In,addi...
(Date:11/19/2008)...ELLE, N.Y., Nov. 19 Biotech scient...es to toxicology research to better understand the...organ systems, reports Genetic Engineering & ...nterested in figuring out a new compound,s mechani...e toxicology technique, according to the November ...
(Date:11/18/2008)... Pa., Nov. 18 Arlington Medical Re...ligence for the pharmaceutical and diagnostic,ima...L Behring,s Privigen was,sold in the U.S. during ...,brand of intravenous immune globulin (IVIG) and w... a product created from the blood plasma of thousa...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Cardiome Reports First Quarter Results 19236 1Cardiome Reports First Quarter Results 19236 2Cardiome Reports First Quarter Results 19236 3Cardiome Reports First Quarter Results 19236 4Cardiome Reports First Quarter Results 19236 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 1Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 2Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 3Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 4Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 6Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 8Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 9Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 10Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 11Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 12Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 1Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 2Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 3Quality Lags at Safety Net Hospitals 19232 1Quality Lags at Safety Net Hospitals 19232 2Quality Lags at Safety Net Hospitals 19232 3
..., 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. ...elanoma vaccine clinical trial and data from the P... vaccine clinical trial will be,presented at the 2...3rd annual meeting in Chicago on June 1-5 2007. , ...cal and immunological responses in patients with m...
...e Patients Receiving Combination of,Bavituximab Pl...sponse or Stable Disease - , - 75% of Patients ...ine , ,Achieved Objective Tumor Response...Receiving Combination of Bavituximab Plus , ... Response - , - Trial Results Support Advanc...
Other Medicine Technology:IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 2IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 3IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 4IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 5IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 6Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 2Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 3Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 4Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 5
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003.
Athouritative, on the spot answers for acute care and consultations.
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
Medicine Products: